Clinical trials: Multiple Sclerosis Lesion
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Multiple Sclerosis
3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)
The aim of this study is to compare the 3D OPTIMIZED MPRAGE WMN sequence to "conventional sequences" used in spinal cord analysis.
- Trial name
- WHINUME (NCT05227092)
- Testing
- 3D OPTIMIZED WMN MPRAGE
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting
Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis
This observational study investigates if switching from MabThera® to Rixathon® is associated with changes in disease activity and/or safety in people with multiple sclerosis (MS).
- Conditions
- MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (Relapsing Remitting)
- Trial name
- NCT07235644
- Where
- Sweden
- Volunteers
- 184 people
- Sponsor
- Uppsala University
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Multiple Sclerosis
A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
This study will compare the effect of A4I antagonist and placebo on MRI lesions,on clinical endpoints, and safety in patients with relapsing Multiple Sclerosis (MS).
- Trial name
- NCT00104143
- Testing
- A4I Antagonist
- Where
- 39 sites in Bulgaria, Canada and 7 more
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Pathologic Processes
Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination
Knowledge of the evolution of multiple sclerosis (MS) and its long-term prognostic factors is essential to guide the therapeutic management.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Tomography, Optical Coherence, Magnetic Resonance Imaging
- Trial name
- DB-SEP15 (NCT03268096)
- Testing
- Cerebral MRI and Optical Coherence Tomography
- Where
- France
- Volunteers
- 182 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis
Sunphenon in Progressive Forms of Multiple Sclerosis
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an oral placebo treatment…
- Trial name
- SUPREMES (NCT00799890)
- Testing
- Sunphenon EGCG
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Friedemann Paul
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05147220
- Testing
- Remibrutinib, Teriflunomide
- Where
- 200 sites in United States, Argentina and 32 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Clinically Isolated Syndrome
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI
Using an automatic software tool, Pixyl.Neuro, to conduct a retrospective analysis (detection of lesions + segmentation of images + tracking over time) of cerebral MRI images acquired during a prospective study of patients…
- Trial name
- PIXCIS (NCT03438357)
- Testing
- Analysis of cerebral MRI with automatic segmentation software
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Tuberous Sclerosis Complex
Predicting Epileptogenic Tubers in Patients with Tuberous Sclerosis Complex
Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging because ETs lack distinct pathological or genetic markers that differentiate them from other…
- Trial name
- NCT06789419
- Volunteers
- 112 people
- Sponsor
- Beijing Children's Hospital
Relapse Remitting Multiple Sclerosis
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting…
- Trial name
- NCT02038049
- Testing
- VAY736
- Where
- 5 sites in United States, Czechia and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Tuberous Sclerosis Complex, Aspirin
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
There had been much evidence in aspirin controlling tumorous conditions conducted by basic researches, especially through mammilian target of rapamycin (mTOR) pathway.
- Conditions
- Tuberous Sclerosis Complex, Aspirin, Epilepsy, Cognitive Decline
- Trial name
- NCT03356769
- Testing
- Aspirin, AED
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Magnetic Resonance Imaging, Central Nervous System
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
Gadolinium-enhanced magnetic resonance imaging (MRI) is currently the imaging gold standard to detect active inflammatory lesions in multiple sclerosis (MS) patients.
- Conditions
- Magnetic Resonance Imaging, Central Nervous System, Brain, Multiple Sclerosis
- Trial name
- COGITE (NCT03268239)
- Testing
- Additional MRI sequences
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis (MS), Cerebral Small Vessel Diseases
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS).
- Trial name
- NCT07444047
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Oslo University Hospital
Facial Angiofibroma
Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
The aim of the study is to determine the effect and safety of topical rapamycin or calcitriol and their combination for the treatment of TSC-associated facial angiofibroma.
- Trial name
- NCT03140449
- Testing
- Rapamycin, Calcitriol, Rapamycin-calcitriol combination
- Volunteers
- 52 people
- Sponsor
- National Taiwan University Hospital
Multiple Sclerosis
Longitudinal Assessment of Iron Rims in MS Lesions
In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course.
- Trial name
- NCT05123443
- Testing
- Blood sample provided, 7-T MRI scan
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple…
- Trial name
- NCT06846281
- Testing
- Remibrutinib oral treatment, Ocrelizumab
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals